Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

INDIANAPOLIS — Eli Lilly filed lawsuits against compounding pharmacies and an Indianapolis weight loss company over the use of Zepbound and Mounjaro. On April 1, 2025, Lilly filed lawsuits against two ...

B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both ...

We examine the labor market effects of AI chatbots using two large-scale adoption surveys (late 2023 and 2024) covering 11 exposed occupations (25,000 workers, 7,000 workplaces), linked to matched ...

Novo Nordisk A/S shares are staging a comeback after a tumultuous year for the maker of Ozempic and Wegovy. The stock is up ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Eli Lilly will add 12.5 mg and 15 mg single-dose vials of its weight loss drug Zepbound to its LillyDirect platform starting July 7, completing the full range of approved doses. All vial doses, ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

Eli Lilly will start selling the two highest doses of its popular weight-loss drug Zepbound directly to customers online in ...

Part of the appeal of amylin analogs is the potential to drive weight loss without causing the same level of tolerability problems as GLP-1 receptor agonists. Lilly reported relatively low rates of ...

Under Lilly’s savings-card program for commercially insured people who lack coverage for Zepbound, a one-month prescription for Zepbound pens now costs a minimum of $650, up from $550 previously.

Discover why Hims & Hers is leading the telehealth market with strong growth, a loyal user base, and expansion into new ...